{"id":"nadroparin-calcium-and-warfarin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hematoma at injection site"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nadroparin calcium works by potentiating antithrombin III to inactivate factors Xa and IIa, providing rapid anticoagulation. Warfarin inhibits the vitamin K-dependent carboxylation of clotting factors II, VII, IX, and X, resulting in delayed anticoagulation. This combination provides both immediate (nadroparin) and sustained (warfarin) anticoagulation for thromboembolic prevention.","oneSentence":"Nadroparin calcium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing antithrombin III activity, while warfarin is a vitamin K antagonist that inhibits synthesis of vitamin K-dependent clotting factors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:37.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prevention and treatment"},{"name":"Atrial fibrillation with thromboembolic risk"}]},"trialDetails":[{"nctId":"NCT04645550","phase":"PHASE4","title":"Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2020-11-22","conditions":"Cirrhosis, Splenectomy; Status, Venous Thrombosis","enrollment":120},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":"Venous Thromboembolism","enrollment":200},{"nctId":"NCT04067505","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-18","conditions":"May-Thurner Syndrome","enrollment":224},{"nctId":"NCT04976543","phase":"PHASE4","title":"Safety of Anticoagulant Therapy After Endoscopic Treatment","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-02-01","conditions":"Cirrhosis, Portal Vein Thrombosis, Esophageal and Gastric Varices","enrollment":86},{"nctId":"NCT05545475","phase":"","title":"Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-01-01","conditions":"Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding","enrollment":100},{"nctId":"NCT04173429","phase":"PHASE4","title":"Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-01-01","conditions":"Liver Cirrhosis, Portal Vein Thrombosis","enrollment":64},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT02247414","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection","status":"COMPLETED","sponsor":"Yangzhou University","startDate":"2014-09","conditions":"Cirrhosis, Hypertension, Status;Splenectomy","enrollment":124},{"nctId":"NCT02238444","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy","status":"UNKNOWN","sponsor":"Yangzhou University","startDate":"2014-09-01","conditions":"Cirrhosis, Hypertension, Venous Thrombosis","enrollment":60},{"nctId":"NCT02526303","phase":"NA","title":"Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis","status":"WITHDRAWN","sponsor":"Air Force Military Medical University, China","startDate":"","conditions":"Liver Cirrhosis, Portal Vein Thrombosis, Anticoagulation","enrollment":""},{"nctId":"NCT02630095","phase":"PHASE4","title":"The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2015-12","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":96},{"nctId":"NCT02398357","phase":"PHASE4","title":"The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2015-03","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nadroparin Calcium and Warfarin","genericName":"Nadroparin Calcium and Warfarin","companyName":"Shanghai Zhongshan Hospital","companyId":"shanghai-zhongshan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nadroparin calcium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing antithrombin III activity, while warfarin is a vitamin K antagonist that inhibits synthesis of vitamin K-dependent clotting factors; together they provide dual anticoagulation. Used for Thromboprophylaxis in high-risk surgical or medical patients, Treatment of venous thromboembolism, Atrial fibrillation with high thromboembolic risk.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}